Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar. We'll be talking in depth today with some of our Lantern's team and also with our collaborator and ...
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...
A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential ...
A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge). A ...
First-in-class TET2 activator targets DNA damage response in GBM and other cancersStrong preclinical efficacy, brain penetration, and safety profile support clinical advancementStudy led by ...
Although DNA is tightly packed and protected within the cell nucleus, it is constantly threatened by damage from normal metabolic processes or external stressors such as radiation or chemical ...
The human immune system is finely tuned to detect and destroy viral threats. But this same defense system can misfire. When ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results